ROBERT J. MORE - 30 May 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
30 May 2025
Transactions value $
$0
Form type
4
Filing time
02 Jun 2025, 19:22:07 UTC
Previous filing
02 Jun 2025
Next filing
09 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MORE ROBERT J Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 02 Jun 2025 0001207792

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +8K +17.14% $0.00 54.7K 30 May 2025 Direct F1, F2
holding VIR Common Stock 496K 30 May 2025 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +16K $0.00 16K 30 May 2025 Common Stock 16K $4.94 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 The RSUs will vest in full on May 30, 2026.
F3 The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. The reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
F4 The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.